Details

Autor(en) / Beteiligte

• Tap, William D
• Sharma, Maitreyi G
• Vallee, Marc
• Smith, Bryan D
• Sherman, Matthew L
• Ruiz-Soto, Rodrigo
• de Sande, Michiel van
• Randall, R Lor
• Bernthal, Nicholas M
• Gelderblom, Hans

Titel

The MOTION study: a randomized, Phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor

Ist Teil von

• Future oncology (London, England), 2024-03, Vol.20 (10), p.593-601

Ort / Verlag

England: Future Medicine Ltd

Erscheinungsjahr

2024

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm that occurs in the synovium of joints, bursae, or tendon sheaths and is caused by upregulation of the gene. Vimseltinib is an oral switch-control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit the CSF1 receptor. Here, we describe the rationale and design for the Phase III MOTION trial ( ), which aims to evaluate the efficacy and safety of vimseltinib in participants with TGCT not amenable to surgical resection. In Part 1, participants are randomized to receive vimseltinib 30 mg twice weekly or matching placebo for ≤24 weeks. Part 2 is a long-term treatment phase in which participants will receive open-label vimseltinib. Tenosynovial giant cell tumor (or TGCT) is a rare, noncancerous tumor that grows in the soft tissue lining the spaces of joints and bursae (fluid-filled sacs that work to reduce friction in the joints). These tumors are linked to increased levels of a protein called CSF1. While this condition is typically treated with surgery, some patients may not be candidates for surgical removal of the tumor due to factors such as location or complexity of the tumor; therefore, drug treatments are needed to help these patients. Vimseltinib is an investigational oral drug specifically designed to inhibit the receptor to which the CSF1 protein binds. In this article, we describe the rationale and design for a Phase III clinical trial that will test how well vimseltinib works in participants with TGCT who are not candidates for surgery. In the first part of the study, participants are randomly assigned to receive vimseltinib 30 mg twice weekly or a matching placebo (inactive substance) for up to 24 weeks. This first part is blinded, so participants will not know if they are receiving vimseltinib or the placebo. The second part of the study is a long-term treatment phase in which all participants will receive vimseltinib (unblinded). ( ) Vimseltinib is an oral switch-control kinase inhibitor designed to selectively and potently inhibit CSF1R. Here, we describe the rationale and design for the Phase III MOTION trial, which aims to evaluate vimseltinib in participants with TGCT not amenable to surgical resection.